

Comparison of MetAP2 Homologues (mouse = SEQ ID NO:13; rat = SEQ ID NO:17;  
human = SEQ ID NO:12; yeast = SEQ ID NO:14)

1	15 16	30 31	45 46	60 61	75 76	90
mouse	MAGVEQAASFGGHLN	GDLPDDREETSST	AEAAKKRRKKKG	KGAVSAVQQELDKE	GALVDEVAKQLESQA	LEEKERDDDDDEDGDG
rat	MAGVEEASSFGGHLN	RDLPDDREETSST	AEAAKKRRKKKG	KGAVSAGQQELDKE	GTSVDEVAKQLERQA	LEEKEKDDDDDEDGDG
human	MAGVEEVAASGSHLN	GDLPDDREEGAAS	AEAAKKRRKKKG	KGPSAAGEQEPDKES	GASVDEVARQLERSA	LEDERDEDEDDEDGDG
yeast	-----	-----	-----	-----	-----	-----
91	105 106	120 121	135 136	150 151	165 166	180
mouse	DADGATGKKKKKKK	KRGPKVQTDPPSVPI	CDLYPNGVFPKGQEC	EYPPTQDGRTAAMRT	TSEKKALDQASEEI	WNDFREAAEAHRQVR
rat	DGDAAGKKKKKKKK	KRGPRVQTDPPSVPI	CDLYPNGVFPKGQEC	EYPPTQDGRTAAMRT	TSEKKALDQASEEI	WNDFREAAEAHRQVR
human	DGDGATGKKKKKKKK	KRGPKVQTDPPSVPI	CDLYPNGVFPKGQEC	EYPPTQDGRTAAMRT	TSEKKALDQASEEI	WNDFREAAEAHRQVR
yeast	ESKKNKKKKKKKKK	N-----	ELFFDPGKYPEGAWM	DYHQDFNLQRTTDEE	SRYLKRDLEA--EH	WNVKRGAEIHRVR
181	195 196	210 211	225 226	240 241	255 256	270
mouse	KYVMSWIKPGMTMIE	ICEKLEDCSRKLIKE	NGLNAG-----	LA FPTGCSLNNCAAHYT	PNAGDTTVLQYDDIC	KIDFGTHISGRIIDC
rat	KYVMSWIKPGMTMIE	ICEKLEDCSRKLIKE	NGLNAG-----	LA FPTGCSLNNCAAHYT	PNAGDTTVLQYDDIC	KIDFGTHISGRIIDC
human	KYVMSWIKPGMTMIE	ICEKLEDCSRKLIKE	NGLNAG-----	LA FPTGCSLNNCAAHYT	PNAGDTTVLQYDDIC	KIDFGTHISGRIIDC
yeast	RAIKDRIVPGMKLMD	IADMIENTTRKYTGA	ENLLAMEDPKSQGIG	FPTGLSLNHCAAHFT	PNAGDKTVLKYEDVM	KVDYGVQVNGNIIIS
271	285 286	300 301	315 316	330 331	345 346	360
mouse	AFTVTFNPKYDILLT	AVKDATNTGIKAGI	DVRLCDVGEAIEQVM	ESYEVEIDGKTYQVK	PIRNLNHSGISGPYRI	HAGKTVPIVKGGEAT
rat	AFTVTFNPKYDILLK	AVKDATNTGIKAGI	DVRLCDVGEAIEQVM	ESYEVEIDGKTYQVK	PIRNLNHSGISGPYRI	HAGKTVPIVKGGEAT
human	AFTVTFNPKYDILLK	AVKDATNTGIKAGI	DVRLCDVGEAIEQVM	ESYEVEIDGKTYQVK	PIRNLNHSGISGPYRI	HAGKTVPIVKGGEAT
yeast	AFTVSFDPQYDNLLA	AVKDATYTGTIKEAGI	DVRLTDIGEAIQVM	ESYEVEINGETIYQVK	PCRNLCGHSIAFYRI	HGGKSVPIVKNGDTT
361	375 376	390 391	405 406	420 421	435 436	450
mouse	RMEEGEVYAIETFGS	TGKGVVHDDMECSHY	MKNFEDVGHVPRLPR	TKHLLNVINENFGTL	AFCRRWLDRLGESKY	LMALKNLCDLGIVDP
rat	RMEEGEVYAIETFGS	TGKGVVHDDMECSHY	MKNFEDVGHVPRLPR	TKHLLNVINENFGTL	AFCRRWLDRLGESKY	LMALKNLCDLGIVDP
human	RMEEGEVYAIETFGS	TGKGVVHDDMECSHY	MKNFEDVGHVPRLPR	TKHLLNVINENFGTL	AFCRRWLDRLGESKY	LMALKNLCDLGIVDP
yeast	KMEEGEHFAIETFGS	TGRGYVTAGGEVSHY	ARSAEDHQVMPITLDS	AKNLLKTIDRNFGL	PCRRYLDRLGQEKY	LFALNNLVRHGLIVQD
451	465 466	480				
mouse	YPPLCDIKGSYTAQF	EHTILLRPTCKEVVS	RGDDY--	478		
rat	YPPLCDIKGSYTAQF	EHTILCAQPVKKLSA	EEMTIKT	480		
human	YPPLCDIKGSYTAQF	EHTILLRPTCKEVVS	RGDDY--	478		
yeast	YPPLNDIPGSYTAQF	EHTILLHAHKKEVVS	KGDDY--	421		

Figure 1





Figure 2



A. Glucose

B. Galactose




Figure 3






Figure 4




**A. Glucose**

**B. Galactose**





H174A-MetAP2 requires N-terminal residues 2-57 for inhibition of *map1* $\Delta$  growth under the GAL1 promoter.

Figure 5



The steady state levels of each MetAP2 construct are comparable. Immunoblot comparison of HA-MetAP2 wt, HA-MetAP2 H174A, and MetAP2  $\Delta 2-57$  H174A steady state levels in *map1Δ*.

Figure 6



Overexpression of H174A-MetAP2 under the GPD promoter does not inhibit the growth of *map2Δ*

Figure 7




FIGURE 8






FIGURE 9




Figure 10




Figure 11